Panbela Therapeutics Inc. (OTC: PBLA) Stock On Radar After Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
Investors looking for possibilities in the biopharmaceutical sector have plenty of options to consider, and one of those could be Panbela Therapeutics Inc. (OTC: PBLA). The clinical-stage biopharmaceutical company is involved in the development of disruptive therapeutics meant for patients suffering from urgent unmet needs. On April 22, the company entered the news cycle after it announced that the interim data analysis from its on-going ASPIRE trial would be made…